SCHEMBL12199954

SCHEMBL12199954

CCc1ccc(C(=O)Oc2ccc(S(=O)(=O)c3ccc(OC(=O)c4ccc(CC)cc4)cc3)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.55
KDM4E B2RXH2 1/20 0.55
LMNA P02545 1/20 0.55
HSP90AA1 P07900 1/20 0.55
RECQL P46063 1/20 0.55
POLB P06746 1/20 0.54
PKM P14618 1/20 0.54
ELANE P08246 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TP53 P04637 1/20 0.48
PLG P00747 1/20 0.47
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
PRSS1 P07477 2/20 0.46
KLK1 P06870 1/20 0.46
ALDH1A1 P00352 3/20 0.46
GAA P10253 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
F2 P00734 1/20 0.44
PRSS2 P07478 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12154217 0.88 ALDH1A1 (0.57) MAPTKDM4ELMNAHSP90AA1RECQL
SCHEMBL12154283 0.88 ALDH1A1 (0.57) MAPTKDM4ELMNAHSP90AA1RECQL
SCHEMBL26832415 0.88 ALDH1A1 (0.57) MAPTKDM4ELMNAHSP90AA1RECQL
SCHEMBL12199916 0.88 ALDH1A1 (0.57) MAPTKDM4ELMNAHSP90AA1RECQL
SCHEMBL29993865 0.85 MAPT (0.51) MAPTKDM4ELMNAHSP90AA1RECQL
SCHEMBL25491843 0.83 MAPT (0.58) MAPTKDM4ELMNAHSP90AA1POLB
SCHEMBL12199956 0.83 TP53 (0.52) MAPTKDM4ELMNAHSP90AA1RECQL
SCHEMBL12154284 0.83 TP53 (0.59) MAPTKDM4ELMNAHSP90AA1RECQL
SCHEMBL26832413 0.83 TP53 (0.59) MAPTKDM4ELMNAHSP90AA1RECQL
SCHEMBL11550359 0.83 TP53 (0.59) MAPTKDM4ELMNAHSP90AA1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455061-B2 Optically active compound having polymerizable group and its polymer JNC CORPORATION (JP) 2013-06-04 US disclosed
US-8404316-B2 Polymerizable liquid crystal compound and its polymer JNC CORPORATION (JP) 2013-03-26 US disclosed
US-8366962-B2 Polymerizable liquid crystal compounds having oxiranyl group, polymerizable liquid crystal compositions and polymers JNC CORPORATION (JP) 2013-02-05 US disclosed
US-20110240918-A1 OPTICALLY ACTIVE COMPOUND HAVING POLYMERIZABLE GROUP AND ITS POLYMER CHISSO CORPORATION (JP) 2011-10-06 US disclosed
US-20110147656-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUNDS HAVING OXIRANYL GROUP, POLYMERIZABLE LIQUID CRYSTAL COMPOSITIONS AND POLYMERS CHISSO CORPORATION (JP) 2011-06-23 US disclosed
US-20110086185-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER CHISSO CORPORATION (JP) 2011-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086185-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER CCNT1, POF1B, CCND3 MAPT 2658/4885KDM4E 4051/4885LMNA 2223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.